Skip to content
No results
  • Home
  • About Us
  • Products
    • Battery Material
      • Battery Additives
      • Ether Fluoride Cosolvent
      • Silicon Carbon Anode
    • Display Materials
      • Mixed Liquid Crystal
      • Monomer Liquid Crystal
      • OLED Materials
      • Liquid Crystal Intermediate
      • Polyimide (PI) material
    • Biological Reagent
      • Primary Antibodies
      • Secondary Antibodies
    • Pharmaceutical Intermediates
    • Other Chemicals
  • News
    • Company news
    • Industry news
  • Contact Us
T-Rock
  • Home
  • About Us
  • Products
    • Battery Material
      • Battery Additives
      • Ether Fluoride Cosolvent
      • Silicon Carbon Anode
    • Display Materials
      • Mixed Liquid Crystal
      • Monomer Liquid Crystal
      • OLED Materials
      • Liquid Crystal Intermediate
      • Polyimide (PI) material
    • Biological Reagent
      • Primary Antibodies
      • Secondary Antibodies
    • Pharmaceutical Intermediates
    • Other Chemicals
  • News
    • Company news
    • Industry news
  • Contact Us
Contact Us
T-Rock
Home Pharmaceutical Intermediates Gadolinium DOTA meglumine

Gadolinium DOTA meglumine

CAS: 92943-93-6

Category: Pharmaceutical Intermediates

Related products

  • Lysergol

    CAS: 602-85-7

    • Pharmaceutical Intermediates

  • 2-Amino-3-fluoro-4-(hydroxymethyl)pyridine

    CAS: 1603015-23-1

    • Pharmaceutical Intermediates

  • 5-(1,1-Dimethylheptyl)resorcinol

    CAS: 56469-10-4

    • Pharmaceutical Intermediates

  • Benzonitrile, 5-bromo-2,3,4-trifluoro-

    CAS: 1503508-74-4

    • Pharmaceutical Intermediates

Technological innovation for the benefit of mankind. --- Changsha T-rock Biochem Co., Ltd

Quick Links

  • Home
  • About Us
  • Contact Us
  • Products
    • Primary Antibodies
  • Blog
Contact Us

Need help or have a question?

Email: INFO@T-ROCKCHEM.COM
ADD: XIDI BUILDING, NO.8 FENGLIN SAN ROAD, YUELU DISTRICT, CHANGSHA CITY, HUNAN PROVINCE,CHINA

Copyright © 2024 - T-Rock 

If you need anything, please contact us.

Please enable JavaScript in your browser to complete this form.
Loading